Today's Breaking News
- Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer
- Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
- Sosei Provides Update on HTL0018318
Latest R&D and Business News
- Amygdala Neurosciences Announces the $12.4 Million HEAL Initiative Sponsored SEARCH (Safety and Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People with Opioid Use Disorder) Program of Phase 2 Clinical Studies
- Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
- Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia
- Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy
- Integral Molecular Partners with Merus to Discover Novel Therapeutic Monoclonal Antibodies
- Agenus Receives Milestone Payment from Incyte
- Camurus Announces Positive Topline Phase 3 Results for CAM2038 in Opioid Experienced Patients With Chronic Low-back Pain
- CBT Pharmaceuticals Initiates the APOLLO Oncology Clinical Trials Program
- BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round
- Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer
- GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier
- Sun Pharma Announces Receipt of European Commission Approval For ILUMETRI® (tildrakizumab) By Almirall For Treatment Of Moderate-To-Severe Chronic Plaque Psoriasis